AQEMIA

AQEMIA is a drug discovery company that generates and evaluates candidate molecules with a platform it calls QEMI, which combines generative AI with fast physics based prediction. Rather than relying on historical training data alone, QEMI uses novel mathematics derived from quantum mechanics to predict molecular behavior, and the company states this delivers physics level accuracy up to 10,000 times faster than conventional computational methods. The platform matters to pharmaceutical and biotechnology organizations seeking differentiated therapies with wide therapeutic windows. QEMI generates molecules tailored to a specific target while maintaining selectivity against anti targets, and it learns from each discovery program so the platform improves as the pipeline grows. AQEMIA applies it to its own internal pipeline across multiple therapeutic areas, and the underlying science comes from more than a decade of academic research at Oxford, Cambridge and ENS and CNRS in Paris. The company operates from Paris and London. AQEMIA does not sell software licenses and publishes no pricing. It works through its internal pipeline and partnerships, and partnership inquiries go to the company directly. This is a biotech with a proprietary platform rather than a tool that other teams can run themselves, so it belongs in an evaluation of discovery partners, not of software vendors.